Compared with CD19 single-target CAR-T cells, both tandem and bicistronic designs demonstrated superior inhibition of JeKo-1 tumors; however, these designs showed a slightly reduced ability to recognize tumor cells positive for either CD19 or CD79a alone. The gene discussed is CD19; the disease is neoplasm.